Kellie Ryan’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (1)


Table 2 Overview of assessments of technologies 
An assessment of the future impact of alternative technologies on antibiotics markets
  • Article
  • Full-text available

October 2016

·

118 Reads

·

16 Citations

Journal of Pharmaceutical Policy and Practice

Ejike Nwokoro

·

Ross Leach

·

Christine Årdal

·

[...]

·

Background The increasing threat of antimicrobial resistance combined with the paucity of new classes of antibiotics represents a serious public health challenge. New treatment technologies could, in theory, have a significant impact on the future use of traditional antibiotics, be it by facilitating rational and responsible use or by product substitution in the existing antibiotics markets, including by reducing the incidence of bacterial infections through preventative approaches. The aim of this paper is to assess the potential of alternative technologies in reducing clinical use of and demand for antibiotics, and to briefly indicate which segments of the antibiotics market that might be impacted by these technologies. Methods An initial mapping exercise to identify the alternative technologies was followed by a review of relevant published and grey literature (n = 52). We also carried out stakeholder engagement activities by a round-table discussion with infectious disease specialists and a multi-criteria decision analysis exercise with pharmaceutical industry experts. Results Ten alternative technologies were identified and analyzed for their potential impact on the antibiotics market. Of these, rapid point-of-care diagnostics, vaccines, fecal microbiota transplantation, and probiotics were considered to have a “high” or “medium” potential impact over a 10-20 year horizon. Therapeutic antibodies, antibiotic biomaterials, bacteriophages, antimicrobial nanoparticles, antimicrobial peptides, and anti-virulence materials were rated as having “low” potential impact. Conclusion Despite the apparent potential of the most promising alternative technologies to reduce demand, that reduction will likely only happen in limited segments of the antibiotics market or, in the case of preventing community acquired streptococcal infections by vaccination, in a low-price generics market segment. Thus, alternative technologies are not expected to represent any disincentive to antibiotics developers. Finally, it is unlikely that alternative technologies will displace the need for new classes, and sub-classes, of antibiotics in the short and medium terms.

Download

Citations (1)


... Currently, there are more than 100 different active substances on the market, classified as antibiotics. Taking into account the form of release and dosages, the number of drugs exceeds 1,700 names [32]. According to statistics, the volume of consumption of PBX-group "Antibacterial drugs for systemic use" in 2020 amounted to 82 billion rubles, which corresponds to 548 million packages of drugs. ...

Reference:

Analysis of the Antimicrobial Drugs Market in Russia
An assessment of the future impact of alternative technologies on antibiotics markets

Journal of Pharmaceutical Policy and Practice